A Phase II Randomized, Double-blind (Part A, B and C), Placebo Controlled (Part A and B Only), Study to Assess Safety, Tolerability and Efficacy of MCS110 on Tumor Size in Patients With Pigmented Villonodular Synovitis (PVNS)

Trial Profile

A Phase II Randomized, Double-blind (Part A, B and C), Placebo Controlled (Part A and B Only), Study to Assess Safety, Tolerability and Efficacy of MCS110 on Tumor Size in Patients With Pigmented Villonodular Synovitis (PVNS)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 May 2017

At a glance

  • Drugs MCS 110 (Primary)
  • Indications Pigmented villonodular synovitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 03 May 2017 Planned number of patients changed from 37 to 39.
    • 03 May 2017 Planned End Date changed from 1 Dec 2018 to 26 Sep 2019.
    • 03 May 2017 Planned primary completion date changed from 1 Dec 2018 to 26 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top